Source comparison
Tesamorelin + Ipamorelin vs Other GH Protocols: Research Application Comparison
Tesamorelin + Ipamorelin Blend Dual GHRH + ghrelin receptor activation 250–500mcg twice daily subcutaneous High. 18–31% visceral fat reduction in 12-week trials Low cortisol/prolactin elevation, minimal water retention at standard doses Best option for targete
This comparison does not assign a generated winner or score.
- Tesamorelin + Ipamorelin Blend
- Dual GHRH + ghrelin receptor activation
- 250–500mcg twice daily subcutaneous
- High. 18–31% visceral fat reduction in 12-week trials
- Low cortisol/prolactin elevation, minimal water retention at standard doses
- Best option for targeted visceral fat research with favorable safety margin. Synergistic mechanism reduces per-peptide dose requirements
- Tesamorelin Monotherapy
- GHRH analog. Direct pituitary GH stimulation
- 2mg once daily subcutaneous
- Moderate-High. 15–18% visceral fat reduction (FDA trials in HIV lipodystrophy)
- Well-tolerated, occasional injection-site reactions, rare glucose intolerance
- Proven clinical efficacy but lacks the receptor diversity of blended protocols. Single-pathway stimulation limits GH pulse amplitude
- Ipamorelin Monotherapy
- Ghrelin mimetic. GHS-R1a activation
- 200–300mcg 2–3x daily
- Moderate. Effective for lean mass preservation, less potent for visceral fat specific targeting
- Minimal. Cleanest side-effect profile among GH secretagogues
- Excellent for recovery and lean tissue research, less effective for visceral adiposity compared to tesamorelin combinations
- CJC-1295 + Ipamorelin
- Long-acting GHRH analog + ghrelin mimetic
- 100–200mcg each, 1–2x daily
- Moderate. Broader GH elevation but less visceral-fat-specific than tesamorelin
- Low. Similar to ipamorelin alone, rare GH-mediated water retention
- Popular research combination but CJC-1295's 6–8 day half-life complicates dose titration and washout compared to tesamorelin's 30-minute half-life
- MK-677 (Ibutamoren) Oral
- Oral ghrelin mimetic. Continuous GHS-R activation
- 10–25mg once daily oral
- Low-Moderate. GH elevation is sustained but lower peak amplitude limits acute lipolytic signaling
- Moderate. Increased appetite, water retention, potential insulin resistance at higher doses
- Convenient oral administration but continuous receptor activation causes desensitization. Less effective for fat-targeted research than pulsatile peptide protocols
- The tesamorelin + ipamorelin blend stands out in research applications requiring measurable visceral fat reduction because tesamorelin's GHRH mechanism specifically targets abdominal adiposity through mechanisms not fully replicated by other secretagogues. The addition of ipamorelin broadens the GH pulse by activating a secondary receptor pathway, creating higher peak GH levels without increasing cortisol or prolactin. The hormonal spillover that limited earlier combinations like GHRP-6 + CJC-1295.